Monash IVF Draws A Second Takeover Approach After Its Crisis Discount

Fund managers say a fresh private equity approach validates the valuation gap created by 2025's embryo transfer errors

30 Jun 2026 · 6 min read

A second indicative takeover approach in April 2026 gave Spheria Asset Management the confirmation it had been waiting for on Monash IVF. The manager, describing the fresh proposal from a consortium backed by private equity player Genesis Capital, said it viewed the approach as tangible validation of the valuation gap it had been highlighting: when the market won't pay up for quality, someone else usually will.

We view this as tangible validation of the valuation gap we have been highlighting - when the market won't pay up for quality, someone else usually will.

— Spheria Asset Management, Monthly Report, June 2026

A cheap entry point built on a rocky history

Tamim Funds Management built its position around the same logic in March 2026, initiating at roughly 64 cents when the second-largest premium fertility provider in Australia, with around 20 per cent market share, traded on 12 times earnings and 5 times EV/EBITDA, historically low multiples following highly publicised lab incidents that had damaged brand trust. The manager noted Genesis Private Equity and Soul Patts had previously bid 80 cents cash but were denied due diligence access, and pointed to the acquirer's history of improving bids, drawing a parallel to the earlier Pacific Smiles takeover, as reason to believe an improved offer was only a matter of time given the consortium's roughly 19 per cent holding.

A takeover bid that came and went

That was not the first approach. Seneca Financial Solutions reported shares rallied 23 per cent in November 2025 after an unsolicited takeover bid at 80 cents a share from a consortium led by Genesis Capital and Washington H. Soul Pattinson, noting Monash IVF had traded at just 6.5 times earnings prior to the bid against comparable industry transactions of 12 to 14 times, making the implied 8 times multiple in the offer still look conservative. The board rejected the approach, and by December 2025 Asymmetric Asset Management reported the consortium had withdrawn the offer entirely, sending the stock down 13.5 per cent. The manager said it had considered the proposal to have merit given Monash IVF's world-leading intellectual property and market share, but had lingering concerns about the company's ability to generate value-creating returns on capital, and chose to sell its holding once the takeover prop was removed, at a price it believed would prove to have been a good one.

We saw Monash IVF as a market leader in a defensive sector with strong demographic tailwinds. The board's decisive action and the opportunity to invest at a significant discount reinforced our conviction in its long-term potential.

— Emanuel Datt, Datt Capital, Article, July 2025

Where the discount originated

The deep valuation gap traces back to a series of embryo transfer errors that first surfaced in mid-2025. Datt Capital said in August 2025 that shares had plunged 25 per cent since April, when a patient at the company's Brisbane clinic unknowingly gave birth to another patient's baby after an embryo mix-up, compounded by a second incident in June involving a patient receiving her own embryo instead of her partner's. The manager bought near the June lows around 60 cents and steadily added to the position, arguing that with roughly 13,000 cycles performed annually, the error rate behind two mistakes remained very low even if the incidents themselves were indefensible. Tamim Funds Management's March 2026 update showed the operational fallout had continued to linger, with a 1.8 per cent revenue decline in the first half of FY26 and a larger EBITDA hit from elevated costs and legal expenses, performance hit hardest in Victoria and New South Wales while Asia and some other Australian states remained resilient.

What managers are watching next

With a second takeover approach now on the table and management focused on stabilising new patient registrations, extracting a targeted 5 per cent EBITDA margin improvement and finalising incident settlements, the key questions for managers are whether Genesis Capital's renewed interest ultimately produces a higher bid than the previously withdrawn 80 cents, and whether the operational recovery Tamim Funds Management is tracking continues regionally even as the legal and reputational overhang from the embryo incidents is worked through.